Lipella pharmaceuticals re-signs manufacturing collaboration agreement with cook myosite to support lp-310 clinical development

Pittsburgh, june 04, 2025 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with cook myosite, inc. (“cook myosite”) to support chemistry, manufacturing and control (cmc) documentation supporting our clinical products lp-10 and lp-310. dr. jonathan kaufman, chief executive officer and co-founder of lipella, said, “we are pleased to renew our collaboration with cook myosite, a trusted partner with a strong track record in high-quality manufacturing.
LIPO Ratings Summary
LIPO Quant Ranking